ZZ-FIRST Trial Protocol: Talazoparib, Enzalutamide, and ADT in mHNPC
Researchers investigating advanced prostate cancer treatments have published findings from the ZZ-FIRST trial, a multicenter phase 2 clinical study evaluating the addition of the PARP inhibitor talazoparib to enzalutamide and ... Read More